Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Jardiance Joy Boosts Boehringer Ingelheim

Executive Summary

Leading the pack with partner Lilly in the expansion of diabetes medication into cardiovascular protection, Boehringer Ingelheim looks set to build this year on its healthy 2016 growth. The completion of its acquisition of Sanofi's Mérial animal health business in January will also boost future sales.

You may also be interested in...



Boehringer Taps Gubra For Early-Stage Obesity Deal

Boehringer Ingelheim has signed a collaboration with Denmark-based Gubra focusing on the development of peptides to treat obesity, with Gubra to receive up to €250m in upfront and potential milestone payments.

Cardiovascular Benefits of SGLT2 Inhibitors: A Class Effect?

The first large real-world evidence study has found SGLT2 inhibitors cut the rate of hospitalizations for heart failure and all-cause mortality in patients at low risk of cardiovascular events, but the results of CV outcomes studies are awaited to confirm the findings.

BI/Lilly's Jardiance Is First Diabetes Drug With CV Benefit Claim

Companies are supporting new US-labeled indication for cardiovascular mortality risk reduction with a consumer education campaign, direct-to-consumer advertising and cardiologist detailing.

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC098531

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel